

### **Reverse transcription polymerase chain reaction (RT-PCR)**

Total RNA was extracted from the CSCs and the swine heart tissues post-treatment using an RNeasy Kit (Qiagen, Hilden, Germany), then reverse-transcribed using Omniscript Reverse Transcriptase (Qiagen) and amplified using the Gene Amp (R) PCR System 9700 (Life Technologies, Tokyo, Japan). The primer pairs were as follows: human-specific KDR primer sequence, sense CCT CTA CTC CAG TAA ACC TGA TTG GG, antisense TGT TCC CAG CAT TTC ACA CTA TGG; human-specific CXCR4 primer sequence, sense ACG TCA GTG AGG CAG ATG, antisense GAT GAC TGT GGT CTT GAG; human GAPDH primer sequence, sense AAT GGG CAG CCG TTA GGA AA, antisense GCG CCC AAT ACG ACC AAA TC; swine-specific SDF-1 primer sequence, sense CCG AAC TGT GCC CTT CAG AT, antisense ATA AAC ATC CCG CCG TCC TC; swine-specific CXCR-4 primer sequence, sense GCG CAA AGC TCT CAA AAC CA, antisense CAG TGG AAA AAG GCA AGG GC; swine-specific VEGF primer sequence, sense GAC GTC TAC CAG CGC AGC TAC T, antisense TTT GAT CCG CAT AAT CTG CAT G; swine-specific IGF-1 primer sequence, sense ACA TCC TCT TCG CAT CTC TTC TAC TT, antisense CCA GCT CAG CCC CAC AGA; swine GAPDH primer sequence, sense CTG CAC CAC CAA CTG CTT AGC, antisense GCC ATG CCA GTG AGC TTC C. The transcript level of gapdh was used as an endogenous reference. The products from the cultured CSCs were stained with ethidium bromide, separated by electrophoresis on an agarose gel, and quantified.

### **Fluorescence in-situ hybridization (FISH)**

Paraffin-embedded sections were predenatured, dehydrated, and then labeled with deoxyribonucleic acid probes, a Cy3-conjugated probe for human-specific genome, Cy5-

conjugated probe for swine-specific genome (Chromosome Science Laboratory, Hokkaido, Japan), and mouse anti-cTn-I or rabbit anti-vWF. The sections were visualized with secondary antibodies conjugated to Alexa fluorochromes. Nuclei were labeled with 4,6-diamino-2-phenylindole (DAPI, Molecular Probes).

### **Statistical analysis**

Continuous data are summarized as medians with ranges (minimums to maximums) or means  $\pm$  SEM (standard error of mean) and are plotted in figures with raw values or barplots of the means with symmetric SEM bars, as appropriate. Distributions of the continuous data were checked for normality with the Shapiro-Wilk test and for equality of between-group variances with the Levene test. Normally distributed data were compared between four groups using the analysis of variance (ANOVA), followed by the Tukey multiple comparison for equal variances, or Welch's ANOVA, followed by the Games-Howell multiple comparison for unequal variances. Non-normally distributed data were compared using the Kruskal-Wallis test, followed by the Steel-Dwass multiple comparison. Normally and Non-normally distributed data before and after treatment were compared using the paired t-test and the Wilcoxon signed rank-sum test, respectively. All P values are 2-sided, and values of P less than 0.05 were considered to indicate statistical significance. All analyses were performed with the SPSS 11.0J for Windows (SPSS, Chicago, IL) and the R program (10).

## RESULTS

### **Human atrium-derived c-kit-positive cells showed CSC characteristics *in vitro***

The isolated right-atrium-derived cells were characterized *in-vitro* by FACS, immunohistolabeling, and RT-PCR analyses. The proportion of C-kit-positive cells at the second passage was  $99 \pm 4\%$  (Figure 1A and 1B). However, as the cells expanded, they lost the primitive phenotype, and more than half of them had the potential to differentiate to the endothelial rather than the cardiomyocyte or smooth muscle cell lineage. The proportion of c-kit-positive cells at the fifth passage was  $20 \pm 10\%$ , while 34%, 71%, and 99% of them expressed CD34, CD31, and CD105, respectively (Figure 1C). Immunohistochemistry revealed that approximately 5% of the cells expressed cTn-I in the cytoplasm (Figure 1D). In addition, RT-PCR clearly revealed the expression of CXCR4 and KDR in the cells (Figure 1E).

After incubating the cells on temperature-responsive dishes at 37°C for 12 hours, CSC sheets were generated by lowering the temperature. Each cell sheet was approximately 42 mm in diameter, and the gap-junction protein connexin 43 was expressed between the cells (Figure 1F). Most of the cells expressed the proliferation marker Ki67 in their nucleus (Figure 1G).

### **Successful cell transplantation with minimal arrhythmogenicity**

A total of 44 pigs underwent treatment, which was performed without any procedure-related mortalities (n=11 each). Fatal arrhythmias, such as ventricular tachycardia and fibrillation, or composite ventricular arrhythmias (grades 3-5 in Lown's classification) were not detected in

any group during the first 24 hours post-treatment, as assessed by Holter ECG monitoring (n=6 each) (Table 1). There were no significant differences in the heart rate or number of unifocal premature ventricular/atrial contractions among the groups.

### **Global functional recovery after CSC-sheet transplantation was enhanced by EPC injection**

Multi-detector CT measured LVESV, LVEDV, and LVEF, and cardiac catheterization measured the systolic parameters dP/dt max, end-systolic pressure-volume relation (ESPVR), and diastolic parameters:  $\tau$ , end-diastolic pressure (EDP), and dP/dt min. There were no significant differences in LVESV, LVEDV, or LVEF among the groups pre-treatment (Figure 2A to 2C). The pigs treated with the sham operation developed increases in LVESV ( $P<0.001$ ) and LVEDV ( $P<0.001$ ) but not in LVEF ( $34\pm 5$  to  $32\pm 6$  %,  $P=0.44$ ) in 8 weeks. In contrast, the pigs in the EPC-only or CSC-only group showed preserved LVESV (EPC-only,  $P=0.23$ ; CSC-only,  $P=0.89$ ), LVEDV (EPC-only,  $P=0.15$ ; CSC-only,  $P=0.13$ ), and LVEF (EPC-only,  $37\pm 5$  to  $37\pm 4$ ,  $P=0.91$ ; CSC-only,  $36\pm 4$  to  $43\pm 5$  %,  $P=0.12$ ). Moreover, the combined treatment induced a significant decrease in LVESV ( $P=0.04$ ) and a significant increase in LVEF ( $36\pm 5$  to  $53\pm 3$  %,  $P=0.001$ ) in the 8 weeks following cell transplantation.

At 8 weeks post-treatment, the LVESV of the CSC-only and EPC-only groups was significantly smaller than that of the sham group, and the LVESV of the CSC-EPC group was even smaller than that of the EPC-only group ( $P<0.001$  for CSC-EPC, CSC-only, and EPC-only vs. sham, and for CSC-EPC vs. EPC-only). The LVEDV of the CSC-EPC, CSC-only, and EPC-only groups was significantly smaller than that of the sham group ( $P=0.001$  for CSC-EPC, CSC-only, and EPC-only vs. sham). The LVEF of the CSC-only group was

significantly greater than that of the sham group, while the LVEF of the CSC-EPC group was even greater than that of the other groups ( $P < 0.001$  for CSC-EPC vs. CSC-only, EPC-only, and sham, and for CSC-only vs. sham). Moreover, the ESPVR of the CSC-EPC group was the greatest, followed by that of the CSC-only group, then the EPC-only group, and then the sham group (Figure 2D).

The  $dp/dt$  max,  $\tau$ , EDP, and absolute value of  $dp/dt$  min were significantly greater in the CSC-EPC group than in the CSC-only and EPC-only groups, and these values except for the absolute value of  $dp/dt$  min were significantly greater in the CSC-only and EPC-only groups than in the sham group (Figure 2E).

#### **Differential region- or layer-specific effects by CSC and EPC transplantation**

Region- or layer-specific systolic LV function was assessed using speckle-tracking echocardiography, which was carried out at pre-treatment and at 4 and 8 weeks post-treatment ( $n=6$ ). There was no significant difference in the endocardial or epicardial wall motion index in the ischemic anterior area among the groups at pre-treatment (Figure 3A and 3B).

The pigs given the sham operation developed a significant decrease in the epicardial wall motion index ( $10 \pm 2$  to  $7 \pm 1$  %,  $P=0.01$ ) and no change in the endocardial wall motion index ( $10 \pm 1$  to  $9 \pm 1$  %,  $P=0.40$ ) in 8 weeks. In contrast, cell transplantation induced a significant increase in epicardial (CSC-only,  $10 \pm 2$  to  $18(14-28)$ ,  $P=0.03$ ; CSC-EPC,  $10 \pm 1$  to  $20 \pm 5$  %,  $P=0.01$ ) and endocardial (EPC-only,  $10 \pm 1$  to  $12 \pm 1$ ,  $P=0.01$ ; CSC-EPC,  $10 \pm 1$  to  $14 \pm 1$  %,  $P=0.001$ ) indices at 8 weeks.

At 8 weeks post-treatment, the epicardial wall motion index of the CSC-EPC and CSC-only groups was significantly greater than that of the EPC-only or sham group ( $P<0.001$  for CSC-EPC and CSC-only vs. EPC-only and sham) (Figure 3A and 3C). In contrast, the endocardial wall motion index of the CSC-EPC group was the greatest followed by that of the EPC-only group, and both were significantly greater than that of the CSC-only or sham group ( $P<0.001$  for CSC-EPC vs. EPC-only vs. CSC-only and sham) (Figure 3B and 3D).

Consistent with these findings, the myocardial perfusion score in the ischemic zone at 8 weeks post-treatment was significantly greater in the CSC-EPC ( $36\pm 1$  dB) than in the sham group ( $19\pm 2$  dB,  $P<0.001$ ) (Figure 3E and 3F).

### **Engraftment of transplanted CSCs and EPCs, and neovascularization of the infarcted wall**

The engraftment of transplanted DiI-red-labeled CSCs and DiI-blue-labeled EPCs was examined, and the capillary density was assessed by fluorescence-based immunohistolabeling for vWF. At 3 weeks after cell transplantation, most of the transplanted CSCs were present over the ischemic area in the sheet shape, although no DiI-red- or DiI-blue-positive cells could be seen in any heart slice at 8 weeks post-treatment (Figure 4A and 4B). The number of vWF-positive capillaries in the ischemic epicardium of the CSC-EPC and CSC-only groups was significantly greater than in the EPC-only or sham group (CSC-EPC,  $251\pm 84$ ; CSC-only,  $257\pm 43$ ; EPC-only,  $105\pm 20$ ; sham,  $112\pm 23$  /mm<sup>2</sup>;  $P=0.001$  for CSC-EPC and CSC-only vs. EPC-only and sham) (Figure 4C). In contrast, the number of capillaries in the ischemic endocardium was significantly greatest in the CSC-EPC, followed

by the EPC-only group, and then by the CSC-only or sham group (CSC-EPC,  $269\pm 11$ ; EPC-only,  $193\pm 14$ ; CSC-only,  $108\pm 30$ ; sham,  $74\pm 38$  /mm<sup>2</sup>;  $P<0.001$  for CSC-EPC vs. EPC-only vs. CSC-only and sham). In association with these findings, some of the transplanted CSCs in both the CSC-EPC and CSC-only groups were observed in native epicardial tissues, while some had migrated into the endocardial tissues only in the CSC-EPC group (Figure 4D). On the other hand, transplanted EPCs in both the CSC-EPC and EPC groups were observed in the ischemic and peri-ischemic area of the endocardium, especially near the vascular wall.

To elucidate the possible mechanism for the transplanted CSC migration, RT-PCR and immunostaining for angiogenic growth factors were performed ( $n=4$  each). The mRNA levels of swine-specific SDF-1, VEGF, and IGF-1 were up-regulated in all the treatment groups (Figure 5A). In particular, the mRNA levels of SDF-1 and the SDF-1 receptor CXCR4, were markedly greater in the CSC-EPC group than in the other groups (SDF-1 or CXCR4:  $P<0.001$  for CSC-EPC vs. CSC-only, EPC-only, and sham). In addition, SDF-1, but not VEGF or IGF-1, was expressed in the cytoplasm of the transplanted CSCs that were present in the native myocardial tissue in the CSC-EPC group (Figure 5B).

### **Preserved myocardial integrity 8 weeks after cell transplantation**

Interstitial fibrosis and capillary density in the heart at 8 weeks post-treatment were assessed by MT (Figure 6A) and PAS (Figure 6B) staining and immunohistolabeling for vWF (Figure 6C), respectively ( $n=6$  each). Excluding the sham group, there were no significant difference in infarct area among the other groups. On the other hand, the accumulation of collagen or area of chronic ischemic injury was the smallest in the CSC-EPC group followed by the CSC-only and EPC-only groups, and then by the sham group (CSC-EPC,  $7\pm 1$ ; CSC-only,

15±3; EPC-only, 20±3; sham 28±5 %; P<0.001 for CSC-EPC vs. CSC-only and EPC-only vs. sham) (Figure 6D). The LV wall thickness was significantly larger in the CSC-EPC group than in the sham group (CSC-EPC, 9±1; sham 7±1 mm; P<0.01 for CSC-EPC vs. sham) (Figure 6E).

The myocyte cell diameter at 8 weeks post-treatment was assessed in the 5-mm heart sections of the remote zone stained by PAS (n=6 each). The myocyte diameter was significantly smaller in the CSC-EPC group than in the CSC-only, the EPC-only, or the sham group (CSC-EPC, 33±9; CSC-only, 49±10; EPC-only, 55±8; sham 61±8 mm; P<0.001 for CSC-EPC vs. CSC-only, EPC-only, and sham) (Figure 6F).

The number of vWF-positive capillaries in the peri-ischemic zone of the CSC-only or EPC only group was greater than that of the sham group, and the number of the CSC-EPC group was even greater than that of the EPC-only or sham group. (CSC-EPC, 83±11; CSC-only, 74±6; EPC-only, 62±8; sham 32±10 /mm<sup>2</sup>; P<0.001 for CSC-only and EPC-only vs. sham, and for CSC-EPC vs. EPC-only and sham) (Figure 6G). In addition, greater vessel formation with vascular lumen was induced in the CSC-EPC group compared with the other groups.

### **Phenotypic fate of transplanted CSCs and EPCs post-transplantation**

The phenotype of the transplanted CSCs and EPCs in the native myocardium at 8 weeks post-transplantation was histologically assessed by human- and/or swine-specific genome-based FISH analysis. Small numbers of cardiomyocytes and endothelial cells with a human genome in the nucleus were present in the native myocardium of both the CSC-EPC and CSC-only groups, but not in the EPC-only group (Figure 7A and 7B). However, there was no



difference in the number of cells with a human genome between the CSC-EPC and CSC-only groups. Of note, all the cells with a human genome in the nucleus also carried a swine genome in the nucleus, which thus had chimeric nuclei (Figure 7C and 7D).

## DISCUSSION

We here demonstrated that primary c-kit-positive CSCs were successfully isolated from the human right atrium and expanded, and showed that they had a differentiation potential for endothelial rather than cardiomyogenic lineages, *in vitro*. Human CSC-sheets were successfully transplanted into the swine chronic ischemic injury heart with minimal arrhythmogenicity, and elicited global functional recovery in 8 weeks. CSC-sheet transplantation concomitant with intramyocardial EPC injection showed enhanced global functional recovery compared with the CSC sheet-only therapy. Transplantation of the CSC sheet alone induced histological reverse LV remodeling, including attenuated interstitial fibrosis and increased vessel numbers, and concomitant EPC injection induced greater reverse LV remodeling effects than the CSC sheet-only therapy. Most of the transplanted CSCs were engrafted onto the surface over the ischemic area, while a small number migrated into the epicardium following the transplantation of the CSC sheet only. In contrast,

concomitant EPC injection enhanced the migration of the transplanted CSCs into the myocardium, in association with local up-regulations of SDF-1, VEGF, and IGF-1. While the CSC of human origin in this study rarely differentiated into the cardiomyocytes in a porcine heart, transplantation of the CSC induced functional and pathological recovery, suggesting that paracrine effects are the major therapeutic mechanisms in this study. Importantly, speckle-tracking echocardiography and histological data indicate that the CSC and the EPC produced different paracrine effects in the failing heart, suggesting synergic effects of these two cell-types as shown in this study.

Clinical cell therapy has been reported to yield only modest functional recovery, as assessed by standard echocardiography (19,22). However, the latest echocardiographic methods, such as strain and contrast echocardiography may better dissect layer-specific regional cardiac functions or myocardial perfusion, leading to a clearer understanding of the functional benefits of cell therapies. The adult mammalian heart is formed in three layers: contractile myocardium, inner endocardium, and outer epicardium. The layers differ in their contribution to cardiac performance and biological function (18). Myocardial infarction affects these myocardial layers to different extents, and ischemic change occurs in a wavefront pattern from the endocardium to the epicardium. In particular, the epicardium is thought to have a rich cardiac progenitor cell niche and to play an important role in cardiac repair (18,24,34). Of note, it has been shown that cell-sheet implantation into the epicardium induces the expression of multiple cardioprotective factors in the heart, and activates host epicardial cells crucial for cardiac repair through ‘cross-talk’ between the implanted cell sheet and the native epicardium (20,33). This delivery method has also been demonstrated to maximize the retention and survival of the transplanted cells and to minimize the risks of

cell-delivery-related myocardial damage (23,27). Thus, we believed that the transplantation of CSCs by the cell-sheet technique might have greater therapeutic effects in a swine chronic ischemic injury model than other delivery methods.

Our layer-specific analysis by strain echocardiography revealed that the CSC-sheet transplantation induced significant functional improvement in myocardial function only in the ischemic epicardium. Consistent with this result, epicardial CSC-sheet implantation induced neovascularization and reduced fibrosis in a paracrine manner in this area. We also observed the migration of transplanted CSCs into the native ischemic epicardium, which suggested that these functional and morphological benefits might be associated with the location of transplanted CSCs in the host myocardium. Previous reports demonstrated that the SDF-1-CXCR4 axis plays an important role in the migration of bone-marrow and cardiac stem cells from the cell sheet to the infarct myocardium (17,28,29). Our data suggested that since migrated CSCs were located in the vicinity of SDF-1 in the host tissue, SDF-1 present in the ischemic tissue might promote the cell migration from the cell sheet to the native ischemic tissues. The strong expression of CXCR4 in the CSC sheet *in vitro* might support this scenario. In fact, the expressions of angiogenic growth factors, including SDF-1, in the chronic ischemic tissues were markedly diminished in the sham group, although these cytokines and adhesion molecules, which play important roles in cardiac repair after injury, are known to be abundant in ischemic tissues at the acute stage of myocardial infarction (1). Thus, these microenvironmental factors in the host cardiac tissue might not greatly contribute to the therapeutic efficacy of the CSC sheet for the chronic ischemic injury model.

In contrast to CSC-sheet transplantation, intramyocardial EPC injection significantly enhanced the improvement in myocardial function only in the ischemic and peri-ischemic

endocardium, and not in the epicardium, in a paracrine manner. Urbich et. al. reported that soluble factors released by EPCs promote the migration of cardiac-resident progenitor cells, using an *in-vitro* migration assay (31). Thus, we considered that EPCs intramyocardially injected into the ischemic endocardium might promote the host tissue's expression of the angiogenic cytokine SDF-1, consequently enhancing the therapeutic efficacy of CSC sheet transplantation by improving the migration of the transplanted CSCs into the native ischemic myocardium.

The graft rate of transplanted EPCs by intramyocardial injection was lower than that of transplanted CSCs by the cell-sheet technique. Transplanted CSCs were uniformly identified in the ischemic epicardium, whereas transplanted EPCs were densely located within the vascular wall of the ischemic and peri-ischemic endocardium. These different graft rates and patterns of transplanted cells might be related to the greater improvement in ESPVR and lower frequency (although not significant) of premature ventricular contraction seen in the animals receiving CSC-sheet implantation alone compared with intramyocardial EPC injection alone, as previously described (20,26). One might think that EPCs could be mixed into the CSC sheet to enhance the CSCs' function; however, we have not been able to generate cell sheets from such mixed cultures. In addition, the injection of EPCs into the endocardial area might be important for attracting the migration of CSCs from the surface to the endocardial area.

In this study, contrast echocardiography dissected the improved myocardial perfusion that was seen 8 weeks after cell transplantation in all the cell therapy groups, but not the sham group. It has been shown that myocardial perfusion is impaired in chronic ischemic cardiomyopathy, and that improved myocardial perfusion is associated with a suppression of

LV remodeling (8). These findings indicate that the therapeutic efficacy in all the cell therapy groups might have been mainly attributable to the suppressive effects on LV remodeling.

Consistent with this idea, multi-detector CT showed that the increased rate of EDV between before and 8 weeks after treatment was less than 20% in all the cell therapy groups, but not in the sham group. On the other hand, invasive hemodynamic assessment using a conductance catheter also showed that CSC-sheet implantation or the intramyocardial injection of EPCs significantly improved measures of LV diastolic functions, such as  $\tau$  and EDP, compared with the sham operation. Previous reports demonstrated that the stiffness of the infarcted myocardium plays an important role in the postinfarction remodeling process (25). Thus, the different types of cell therapy we used may have had a softening effect on the scar tissue by increasing the cellularity, leading to a more pliable scar and less global cardiac remodeling.

In this study, *in-vivo* CSC-sheet implantation or concomitant EPC injection rarely induced the differentiation of transplanted CSCs into cardiomyogenic or vasculogenic lineages. Instead, all of the cardiac protein-expressing transplanted cells arose from fusion with existing myocytes or endothelial cells. Several lines of evidence support the idea that differentiation potential can be altered by differences in the severity of the pretreated infarct, as well as the timing of cell transplantation (20,21). In particular, Matsuura et al. reported that in viable ischemic tissues with existing cardiomyocytes, CSCs are likely to differentiate into myocytes or vascular cells *via* a cell fusion-dependent mechanism (20). Our layer-specific regional functional analysis by strain echocardiography identified residual viability in the ischemic area just before the cell therapies, and these conditions might have limited the differentiation potential of the CSC sheet *in vivo* and the ability of additional EPC injection to promote the differentiation of CSCs into the cardiomyogenic or vasculogenic lineages.

A potential limitation of this study is that the human c-kit-positive CSCs were obtained from a single donor. However, the isolation and culture methods for the primary c-kit-positive CSCs used in this study were previously established to yield CSCs of consistent functionality regardless of the donor (30). The findings of this study are therefore likely to be consistent with those obtained using CSCs from a different donor. In addition, although the swine were immunosuppressed by a previously reported regimen (15), xenogeneic cell transplantation might limit or exaggerate the therapeutic efficacy of the treatment. However, our analysis of layer-specific regional function clearly demonstrated the previously undescribed therapeutic benefit that additional EPC injection improves the CSC-sheet therapy for the swine ischemic injury model.

In summary, CSC transplantation by the cell-sheet technique prevented LV remodeling, through increased neovascularization and reduced fibrosis in a paracrine manner, and consequently improved the global LV function, and these effects were further enhanced by combination therapy with EPC injection. Our layer-specific strain analysis revealed that CSC-sheet implantation improved regional wall motion in the epicardium, but not the endocardium. However, concomitant EPC transplantation significantly enhanced the therapeutic potential of CSC-sheet therapy in endocardium. Concomitant EPC injection promoted migration of transplanted CSCs into the host myocardium, which might contribute to enhancement of functional recovery in the endocardium by the combination therapy. The combination of CSC-sheet implantation and intramyocardial EPC injection may represent a promising strategy for ischemic cardiomyopathy.

## **ACKNOWLEDGEMENT**

We thank Mr. Tsuyoshi Ishikawa for cell culturing, and Mr. Shigeru Matsumi for excellent technical assistance for the surgery and care of the animals.

## **FUNDING SOURCES**

This study was financially supported by a Grant-in-Aid of Scientific Research (08062134) from the Ministry of Health, Labour, and Welfare of Japan.

## **DISCLOSURE**

Mr. Akima Harada is a full-time employee of CellSeed Inc, Japan. Mr. Tatsuya Shimizu and Mr. Teruo Okano are members of the scientific advisory board of CellSeed Inc, Japan.

## REFERENCES

1. Abbott, J. D.; Huang, Y.; Liu, D.; Hickey, R.; Krause, D. S.; Giordano, F. J. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. *Circulation* 110(21):3300-3305; 2004.
2. Adamu, U.; Schmitz, F.; Becker, M.; Kelm, M.; Hoffmann, R. Advanced speckle tracking echocardiography allowing a three-myocardial layer-specific analysis of deformation parameters. *Eur. J. Echocardiogr.* 10(2):303-308; 2009.
3. Becker, M.; Altiok, E.; Lente, C.; Otten, S.; Friedman, Z.; Adam, D.; Hoffmann, R.; Koos, R.; Krombach, G.; Marx, N. Layer-specific analysis of myocardial function for accurate prediction of reversible ischaemic dysfunction in intermediate viability defined by contrast-enhanced MRI. *Heart* 97(9):748-756; 2011.
4. Becker, M.; Ocklenburg, C.; Altiok, E.; Futing, A.; Balzer, J.; Krombach, G.; Lysyansky, M.; Kuhl, H.; Krings, R.; Kelm, M.; Hoffmann, R. Impact of infarct transmuralty on layer-specific impairment of myocardial function: a myocardial deformation imaging study. *Eur. Heart J.* 30(12):1467-1476; 2009.
5. Bel, A.; Planat-Bernard, V.; Saito, A.; Bonnevie, L.; Bellamy, V.; Sabbah, L.; Bellabas, L.; Brinon, B.; Vanneaux, V.; Pradeau, P.; Peyrard, S.; Larghero, J.; Pouly, J.; Binder, P.; Garcia, S.; Shimizu, T.; Sawa, Y.; Okano, T.; Bruneval, P.; Desnos, M.; Hagege, AA.; Casteilla, L.; Puceat, M.; Menasche, P. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. *Circulation* 122(11 Suppl):S118-123; 2010.
6. Bolli, R.; Chugh, A. R.; D'Amario, D.; Loughran, J. H.; Stoddard, M. F.; Ikram, S.; Beache, G. M.; Wagner, S. G.; Leri, A.; Hosoda, T.; Sanada, F.; Elmore, J. B.;



- Goichberg, P.; Cappetta, D.; Solankhi, N. K.; Fahsah, I.; Rokosh D. G.; Slaughter, M. S.; Kajstula, J.; Anversa, P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet* 378(9806):1847-1857; 2011.
7. Dib, N.; Khawaja, H.; Varner, S.; McCarthy, M.; Campbell, A. Cell therapy for cardiovascular disease: a comparison of methods of delivery. *J. Cardiovas. Transl. Res.* 4(2):177-181; 2011.
  8. Galiuto, L.; Garramone, B.; Scara, A.; Rebuzzi, A. G.; Crea, F.; La Torre, G.; Funaro, S.; Madonna, M.; Fedele, F.; Agati, L. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. *J. Am. Coll. Cardiol.* 51(5):552-559; 2008.
  9. Hosoda, T.; Zheng, H.; Cabral-da-Silva, M.; Sanada, F.; Ide-Iwata, N.; Ogorek, B.; Ferreira-Martins, J.; Arranto, C.; D'Amario, D.; del Monte, F.; Urbanek, K.; D'Alessandro, D. A.; Michler R. E.; Anversa, P.; Rota, M.; Kajstura, J.; Leri, A. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. *Circulation* 123(12):1287-1296; 2011.
  10. Imanishi, Y.; Miyagawa, S.; Meaeda, N.; Fukushima, S.; Kitagawa-Sakakida, S.; Daimon, T.; Hirata, A.; Shimizu, T.; Okano, T.; Shimomura, I.; Sawa, Y. Induced adipocyte cell-sheet ameliorates cardiac dysfunction in a mouse myocardial infarction model: a novel drug delivery system for heart failure. *Circulation* 124[ suppl 1]:S10-S17; 2011.
  11. Iwasaki, H.; Kawamoto, A.; Ishikawa, M.; Oyamada, A.; Nakamori, S.; Nishimura, H.; Sadamoto, K.; Horii, M.; Matsumoto, T.; Murasawa, S.; Shibata, T.; Suehiro, S.;

- Asahara, T. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. *Circulation* 113(10):1311-1325; 2006.
12. Kawaguchi, N.; Smith, A. J.; Waring, C. D.; Hasan, M. K.; Miyamoto, S.; Matsuoka, R.; Ellison, G. M. c-kit<sup>pos</sup> GATA-4 high rat cardiac stem cells foster adult cardiomyocyte survival through IGF-1 paracrine signalling. *PloS one* 5(12):e14297; 2010.
  13. Kawamoto, A.; Iwasaki, H.; Kusano, K.; Murayama, T.; Oyamada, A.; Silver, M.; Hulbert, C.; Gavin, M.; Hanley, A.; Ma, H.; Kearney, M.; Zak, V.; Asahara, T.; Losordo, D. W. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. *Circulation* 114(20):2163-2169; 2006.
  14. Kempny, A.; Diller, G. P.; Kaleschke, G.; Orwat, S.; Funke, A.; Radke, R.; Schmidt, R.; Kerckhoff, G.; Ghezelbash, F.; Rukosujew, A.; Reinecke, H.; Scheld, H. H.; Baumgartner, H. Longitudinal left ventricular 2D strain is superior to ejection fraction in predicting myocardial recovery and symptomatic improvement after aortic valve implantation. *Int. J. Cardiol.*; 2012.
  15. Kim, B. O.; Tian, H.; Prasongsukarn, K.; Wu, J.; Angoulvant, D.; Wnendt, S.; Muhs, A.; Spitkovsky, D.; Li, R. K. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. *Circulation* 112(9 Suppl):I96-104; 2005.
  16. Kobayashi, H.; Shimizu, T.; Yamato, M.; Tono, K.; Masuda, H.; Asahara, T.; Kasanuki, H.; Okano, T. Fibroblast sheets co-cultured with endothelial progenitor

- cells improve cardiac function of infarcted hearts. *J. Artif. Organs* 11(3):141-147; 2008.
17. Li, N.; Lu, X.; Zhao, X.; Xiang, F. L.; Xenocostas, A.; Karmazyn, M.; Feng, Q. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. *Stem Cells*. 27(4):961-970; 2009.
18. Limana, F.; Zacheo, A.; Mocini, D.; Mangoni, A.; Borsellino, G.; Diamantini, A.; De Mori, R.; Battistini, L.; Vigna, E.; Santini, M.; Loiaconi, V.; Pompilio, G.; Germani, A. Capogrossi, M. C. Identification of myocardial and vascular precursor cells in human and mouse epicardium. *Circ. Res.* 101(12):1255-1265; 2007.
19. Makkar, R. R.; Smith, R. R.; Cheng, K.; Malliaras, K.; Thomson, L. E.; Berman, D.; Czer, L. S.; Marban, L.; Mendizabal, A.; Johnston, P. V.; Russell, S. D.; Schuleri, K. H.; Lardo, A. C.; Gerstenblith, G.; Marban, E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet* 379(9819):895-904; 2012.
20. Matsuura, K.; Honda, A.; Nagai, T.; Fukushima, N.; Iwanaga, K.; Tokunaga, M.; Shimizu, T.; Okano, T.; Kasanuki, H.; Hagiwara, N. Komuro, I. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. *J. Clin. Invest.* 119:2204-2217; 2009.
21. Matsuura, K.; Wada, H.; Nagai, T.; Iijima, Y.; Minamino, T.; Sano, M.; Akazawa, H.; Molkenkin, J. D.; Kasanuki, H.; Komuro, I. Cardiomyocytes fuse with surrounding noncardiomyocytes and reenter the cell cycle. *J. Cell Biol.* 167(2):351-363; 2004.
22. Meyer, G. P.; Wollert, K. C.; Lotz, J.; Steffens, J.; Lippolt, P.; Fichtner, S.; Hecker, H.; Schaefer, A.; Arseniev, L.; Hertenstein, B.; Ganser, A.; Drexler, H. Intracoronary

- bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. *Circulation* 113(10):1287-1294; 2006.
23. Miyagawa, S.; Saito, A.; Sakaguchi, T.; Yoshikawa, Y.; Yamauchi, T.; Imanishi, Y.; Kawaguchi, N.; Teramoto, N.; Matsuura, N.; Iida, H.; Shimizu, T.; Okano, T.; Sawa, Y. Impaired myocardium regeneration with skeletal cell sheets--a preclinical trial for tissue-engineered regeneration therapy. *Transplantation* 90(4):364-372; 2010.
  24. Russell, J. L.; Goetsch, S. C.; Gaiano, N. R.; Hill, J. A.; Olson, E. N.; Schneider, J. W. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. *Circ. Res.* 108(1):51-59; 2011.
  25. Schneider, C.; Jaquet, K.; Geidel, S.; Rau, T.; Malisius, R.; Boczor, S.; Zienkiewicz, T.; Kuck, K. H.; Krause, K. Transplantation of bone marrow-derived stem cells improves myocardial diastolic function: strain rate imaging in a model of hibernating myocardium. *J. Am. Soc. Echocardiogr.* 22(10):1180-1189; 2009.
  26. Sekine, H.; Shimizu, T.; Dobashi, I.; Matsuura, K.; Hagiwara, N.; Takahashi, M.; Kobayashi, E.; Yamato, M.; Okano, T. Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. *Tissue Eng. Pt. A* 17(23-24):2973-2980; 2011.
  27. Shimizu, T.; Sekine, H.; Yamato, M.; Okano, T. Cell sheet-based myocardial tissue engineering: new hope for damaged heart rescue. *Curr. Pharm. Design* 15(24):2807-2814; 2009.
  28. Son, B. R.; Marquez-Curtis, L. A.; Kucia, M.; Wysoczynski, M.; Turner, A. R.; Ratajczak, J.; Ratajczak, M. Z.; Janowska-Wieczorek, A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived